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Abstract
Aims To assess treatment decision and outcome in patients
referred for transcatheter aortic valve implantation (TAVI)
in addition to predictive factors of mortality after TAVI.
Methods Three-centre prospective observational study in-
cluding 358 patients. Endpoints were defined according to
the Valve Academic Research Consortium.
Results Of the 358 patients referred for TAVI, TAVI was
performed in 235 patients (65%), surgical aortic valve
replacement (AVR) in 24 (7%) and medical therapy (MT)
in 99 (28%). Reasons to decline TAVI in favour of AVR/MT
were patient preference (29%), peripheral vascular disease
(15%) and non-severe aortic stenosis (11%). The logistic
EuroSCORE was significantly higher in patients who under-
went TAVI and MT in comparison with those undergoing
AVR (19 vs. 10%, p=0.007). At 30 days, all-cause mortality
and the combined safety endpoint were 9 and 24% after
TAVI and 8 and 25% after AVR, respectively. All-cause
mortalitywassignificantlylowerintheTAVIgroupcompared
with the MT group at 6 months, 1 year and 2 years (12% vs.
22%, 21% vs. 33% and 31% vs. 55%, respectively,
p<0.001). Multivariable analysis revealed that blood trans-
fusion (HR: 1.19; 95% CI: 1.05–1.33), pre-existing renal
failure (HR: 1.18; 95% CI: 1.06–1.33) and STS score (HR:
1.06; 95% CI: 1.02–1.10) were independent predictors of
mortality at a median of 10 (IQR: 3–23) months after TAVI.
Conclusions Approximately two-thirds of the patients
referred for TAVI receive this treatment with gratifying
short- and long-term survival. Another 7% underwent AVR.
Prognosis is poor in patients who do not receive valve
replacement therapy.
Keywords Aortic stenosis.Transcatheter aortic valve
implantation.Surgical aortic valve replacement.Treatment
decision.Complications.Prognosis
Introduction
Transcatheter aortic valve implantation (TAVI) is a catheter-
based treatment for patients with aortic stenosis (AS) who
are considered poor candidates for surgical aortic valve
replacement (AVR). Although it is increasingly being
considered the standard of care in such patients [1], not
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DOI 10.1007/s12471-011-0224-zall patients receive TAVI but instead continue medical
therapy (MT). This may bear important consequences in
terms of prognosis and quality of life.
Historically, the treatment decision heavily depended upon
the assessment of risk of valve replacement by using the
Logistic EuroSCORE (LES) or Society of Thoracic Surgeons
(STS)score[2, 3]. These scores were developed to assess the
operative risk of patients undergoing open-heart surgery but
not for the subset of patients who are referred for TAVI.
Therefore, careful patient-to-patient case evaluation by Heart
Team meetings are strongly encouraged and play a crucial
role in the design of randomised clinical trials [1, 4–7]. In
this study, we sought to explore the reasons for the treatment
decision, the treatment-specific complications and survival in
patients referred for TAVI in addition to the predictive factors
of mortality in those undergoing TAVI.
Methods
Patients and eligibility
The population consists of all 358 patients who were referred
for TAVI at the Department of Cardiology of the Erasmus
Medical Centre, Rotterdam, the Netherlands and the Depart-
ments of Cardiology and Cardio-Thoracic Surgery of Angiog-
rafiadeOccidenteS.A.,Cali,ColombiaandFundacionClinica
Cardio Infantil, Bogota, Colombia between November 2005
and January 2011. In the three institutions, a similar database
and structure of data collection and follow-up was set up at the
initiation of TAVI as previously described [8].
Treatment decision (TAVI, AVR, MT) was taken by
consensus during the Heart Team meeting. Details of
eligibility for Medtronic Corevalve System (MCS) implan-
tation, the bioprosthesis and technique of implantation have
previously been described [8–10]. All patients underwent
transfemoral (n=228) or trans-subclavian TAVI (n=7) with
the 18 Fr third-generation MCS except for the first five
patients treated in 2005 and 2006, in whom a 21 Fr second-
generation MCS was implanted.
AVR was performed through mid-sternotomy using
standard surgical techniques. In all patients a biological
prosthesis was used.
Patients not undergoing valve intervention continued
MT. Balloon aortic valvuloplasty (BAV) was performed in
patients with AS and worsening symptoms as a bridge to
TAVI or as a palliative approach in patients who could not
undergo TAVI/AVR.
Data collection
All data were prospectively collected and entered in a
dedicated database. Source verification of the baseline data
and clinical events was performed by the first author at
each participating centre (within a Master of Science
Programme of the Netherlands Institute for Health
Sciences, Erasmus University Rotterdam, supported by
the Erasmus-Columbus Latin-European Exchange Grant -
www.erasmus-columbus.eu).
All endpoints were selected and defined according to the
Valve Academic Research Consortium (VARC) [11].
Cerebrovascular events were evaluated and adjudicated
by a vascular neurologist. A full blood and chemistry
sample was taken before and up to 3 days after the
procedure to assess the occurrence and severity of peri-
procedural vascular, bleeding and kidney complications.
Data on red blood cell (RBC) transfusions were recorded
by the institution’s blood bank. The occurrence and timing
of new atrial fibrillation and postprocedural 3
rd degree
atrioventricular block was assessed by continuous telemetry
recording.
The VARC combined safety endpoint at 30 days con-
sisted of all-cause death, major stroke, major vascular
complication, life-threatening bleeding, acute kidney injury
(AKI) stage III and any in-hospital re-intervention due to
prosthesis dysfunction (interventional/surgical).
Follow-up
Follow-up information of patients treated at the Erasmus
Medical Centre (TAVI, AVR, MT) was collected by first
checking the vital status via the civil registries every
6 months. In case of survival, a questionnaire was sent to
the patient for the assessment of symptoms, (cardiac) events
and readmission(s). Also surviving patients were contacted
by telephone to confirm hospital readmission and reason
after which events were verified with the treating hospital.
All medical records were revised and general practitioners
were contacted when necessary. Follow-up was complete
for all patients.
Follow-up information of patients treated in Colombia
was obtained by the regular office visit and/or telephone
contact (dedicated local research nurse or doctor) with the
treating physician and/or general practitioner and/or patient
or family followed by verification of the event with the
treating hospital. Follow-up was complete for all except for
3 patients.
Statistical analysis
Categorical variables are presented as frequencies and
percentages and were compared with the Chi-square test
or Fisher’s exact test. Normal and skewed continuous
variables are presented as means ± SD and medians (IQR),
respectively. To compare the three treatment groups,
analysis of variance was used for continuous variables and
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survival methods were used to calculate the cumulative
survival at different time intervals and the log-rank test was
used to assess differences in survival. A stepwise Cox
regression analysis including all variables with p<0.10 in
the univariable analysis was used to determine independent
predictors of late mortality in patients undergoing TAVI. A
two-sided p<0.05 was considered to indicate significance
and all analyses were performed with SPSS software
(version 17.0).
Results
Of the 421 patients, 60 (14%) died on the waiting list at a
median (IQR) of 48 (14–110) days after first medical contact
and 3 (1%) were lost to follow-up. Therefore, the total study
population consists of 358 patients of whom 235 (65%)
underwent TAVI at a median (IQR) interval of 71 (30–119)
daysand24(7%)AVRatanintervalof63(33–122)days.The
remaining 99 patients (28%) continued MT. The reasons why
AVRorMTwaschoseninsteadofTAVIaredepictedinFig.1.
The main reason to reject TAVI in favour of AVR or MT
were patient preference (29%), peripheral vascular disease
(PVD, 13%) and non-severe AS (11%). The baseline
characteristics of the three treatment groups are summarised
in Table 1. Not unexpectedly, patients who underwent TAVI
or continued MT had a significantly higher LES.
Thirty-day clinical outcome
Thirty-day all-cause and cardiovascular mortality was 9 and
6% in the TAVI group and 8 and 8% in the AVR group,
respectively (Table 2). In the TAVI group, six patients
died during the procedure. The cause of death was
hypotension during induction of anaesthesia (n=1), elec-
tromechanical dissociation (n=2), coronary obstruction
(n=1), left ventricular outflow tract rupture (n=1) and
retroperitoneal haemorrhage (n=1). Another 14 patients
died at a median of 7 (IQR: 3–13) days after TAVI due to
stroke (n=3), heart failure (n=2), sudden death (n=2:
unrecognised alternating left and right bundle branch
block leading to asystole at day 8 and sudden death
1 day after discharge on day 29), sepsis (n=2), pneumonia
(n=2), retroperitoneal haemorrhage (n=2) and cardiac
tamponade (n=1). In the surgical group, the cause of
death was ventricular fibrillation (n=1) and severe para-
valvular aortic regurgitation (n=1).
Cardiac re-intervention after the index procedure was
required in 3 patients in the TAVI group: immediate
conversion to AVR (n=1), closure of a paravalvar leak
14 days after TAVI (n=1) and post-implantation dilatation
of the MCS 21 days after TAVI (n=1). In the AVR group,
two patients underwent re-thoracotomy for severe aortic
regurgitation (n=1) and cardiac tamponade (n=1) 1 day
after AVR.
Although the total rate of vascular and bleeding
complications was higher in the TAVI group in comparison
with the AVR group, the combined 30-day safety endpoint
did not differ between the two groups (24 vs. 25%, p=1.0).
Follow-up
The median follow-up was 298 (IQR: 107–688) days in the
TAVI group, 836 (IQR: 327–1269) days in the surgical
group and 456 (IQR: 187–869) days in the medical group.
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Fig. 1 Reasons to decline TAVI
in favour of AVR and MT.
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Estimated survival at 2 years was 80% in the AVR group,
69% in the TAVI group and 45% in patients who continued
MT (p<0.001). The median time between treatment (AVR
or TAVI) or first medical contact (MT) and death was 96
(IQR: 11–679) days in the surgical group, 171 (IQR: 24–
365) days in the TAVI group and 300 (IQR: 98–578) days
in the MT group.
Details of adverse events beyond 30 days are summar-
ised in Table 3. By univariable analysis, PVD, baseline
creatinine, STS score, RBC transfusion and AKI were
identified as potential determinants of mortality after TAVI.
Multivariable analysis retained RBC transfusion (HR: 1.19;
95% CI: 1.05–1.33), pre-existing renal failure (HR: 1.18;
95% CI: 1.06–1.33) and STS score (HR: 1.06; 95% CI:
1.02–1.10) as independent predictors of mortality after
TAVI
Discussion
We found that the majority of patients referred for TAVI
(72%) undergo valve implantation/replacement (TAVI 65%,
AVR 7%) but that nearly 30% continue MT mainly because
of comorbidity and patient preference not to receive TAVI/
AVR. Patients who underwent TAVI had a higher LES than
those who underwent AVR, were more symptomatic with a
higher prevalence of antecedent CABG and impaired renal
function but less PVD. The most frequent complications
after TAVI consisted of bleeding and vascular complications.
With respect to treatment allocation, the present findings
most likely reflect the current ‘real world’ practice. The
two-thirds acceptance and one-third rejection rate contrasts
with randomised studies such as the Placement of AoRTic
TraNscathetER valve (PARTNER) Cohort-B trial in which
only 12% of the referred patients were accepted for
Table 1 Baseline characteristics of patients undergoing TAVI, AVR and medical therapy
TAVI AVR Medical p-value
n=235 N=24 n=99
Age (years), mean ± SD 80±7 78±9 80±8 0.26
Male, n (%) 116 (49) 13 (54) 42 (42) 0.32
Height (cm), mean ± SD 166±11 169±8 166±8 0.50
Weight (kg), mean ± SD 71±13 75±11 69±16 0.14
BMI, mean ± SD 26.7±4 26.4±4 24.9 5 0.34
BSA, mean ± SD 1.81±0.19 1.87±0.15 1.77±0.24 0.14
NYHA class ≥III, n (%) 177 (75) 12 (50) 53 (53) 0.091
Previous MI, n (%) 45 (19) 5 (21) 16 (16) 0.78
Previous CABG, n (%) 54 (23) 0 21 (21) 0.032
Previous PCI, n (%) 60 (26) 5 (21) 26 (26) 0.92
PVD, n (%) 30 (13) 6 (25) 28 (28) 0.002
Diabetes mellitus, n (%) 57 (24) 5 (21) 28 (28) 0.64
Hypertension, n (%) 132 (56) 12 (50) 34 (34) 0.029
Creatinine, mean ± SD 123±131 104±56 129±68 0.75
Chronic haemodialysis, n (%) 11 (5) 1 (5) 0 0.20
COPD, n (%) 78 (33) 5 (21) 31 (31) 0.59
Permanent pacemaker, n (%) 26 (11) 3 (13) 10 (10) 0.96
Atrial fibrillation, n (%) 49 (21) 8 (33) 25 (25) 0.23
Aortic valve area (cm2), mean ± SD 0.67±0.21 0.81±0.39 0.77±0.27 0.001
LV, n (%)
- Poor (EF <30%) 34 (14) 2 (8) 10 (10) 0.89
- Moderate (EF 30–59%) 82 (35) 6 (25) 24 (24) 0.66
Mitral regurgitation grade ≥III, n (%) 28 (12) 2 (8) 5 (5) 0.29
Aortic regurgitation grade ≥III, n (%) 45 (19) 0 3 (3) 0.001
Logistic Euroscore, mean ± SD 19.1±13.7 10.1±4.3 18.9±12.1 0.007
STS score, mean ± SD 6.1±5.5 4.1±2.4 5.8±3.8 0.17
BMI body mass index, BSA body surface area, CABG coronary artery bypass graft, COPD chronic obstructive pulmonary disease, EF ejection
fraction, NYHA New York Heart Association, LV left ventricular, MI myocardial infarction, PCI percutaneous coronary intervention, PVD
peripheral vascular disease, STS Society of Thoracic Surgeons
Neth Heart J (2012) 20:16–23 19randomised treatment allocation. Of note, we observed a
significant increase in acceptance for TAVI from 2006 until
2010; it was 20% in 2006, 33% in 2007, 50% in 2008, 57%
in 2009 and 81% in 2010. This is not explained by
accepting less sick patients since the LES did not change
over time but is most likely explained by increased
experience and familiarity with the procedure in combination
with an increased public awareness resulting in less patients
who refuse therapy. This may also explain that – over time -
less patients were redirected to surgery (29% of the surgical
patients were treated in 2006; 29% in 2007; 25% in 2008;
13% in 2009 and 4% in 2010).
Initially the LES was a critical factor in patient acceptance
but a present consensus on treatment allocation by the Heart
Team has become the dominant factor. This is not surprising
since this score was neither designed nor validated for TAVI
anddoesnotcapturethespectrumofclinicaldetailsallowinga
balanced treatment decision [12, 13]. Also the LES is out of
synchrony with the STS score [12, 14]. The shortcomings of
the risk score models and the value of multidisciplinary
patient discussion are illustrated by the web-based confer-
ence call system used in the United States to review and
Table 2 Thirty-day clinical
outcome in patients undergoing
TAVI and AVR
AV atrioventricular, AVR aortic
valve replacement, BAV balloon
aortic valvuloplasty
Mutually non-exclusive analysis
(≥1 event/patient possible)
1Including TIA
2Closure of severe paravalvar
aortic regurgitation with
Amplatzer closure device
(n=1) in TAVI group and
resternotomy for severe
aortic regurgitation (n=1) and
bleeding (n=1) in AVR group
3For symptoms of valve-related
dysfunction or cardiac
decompensation
4Composite all-cause mortality,
major stroke, major vascular
complication, life-threatening
bleeding, acute kidney injury -
stage 3, peri-procedural myocar-
dial infarction, repeat procedure
for valve-related dysfunction
(surgical or interventional)
TAVI AVR p-value
n=235 n=24
Mortality, n (%)
- All-cause 20 (9) 2 (8) 1.0
- Cardiovascular cause 13 (6) 2 (8) 0.64
Myocardial infarction, n (%)
- All 3 (1) 1 (4) 0.32
- Periprocedural (<72 h) 2 (1) 0 1.0
Cerebrovascular complication, n (%)
- All
1 20 (9) 2 (8) 1.0
- Major stroke 11 (5) 1 (4) 1.0
Vascular complication, n (%)
- All 42 (18) 0 0.036
- Major 24 (10) 0 0.14
Bleeding complication, n (%)
- All 67 (29) 2 (8) 0.049
- Life-threatening or disabling 21 (9) 2 (8) 1.0
Acute kidney injury, n (%)
- All 40 (17) 8 (33) 0.058
- Stage III 5 (2) 2 (8) 0.13
Cardiac re-intervention, n (%)
- AVR 1 (1) 0 1.0
- BAV 1 (1) 0 1.0
- Other
2 1 (1) 2 (8) 0.023
New pacemaker implantation
- All 48 (21) 1 (4) 0.056
- For 3rd degree AV block 40 (17) 0 0.032
New atrial fibrillation 9 (5) 2 (11) 0.60
Repeat hospitalisation, n (%)
3 3 (1) 0 1.0
Combined 30-day safety endpoint, n (%)
4 55 (24) 6 (25) 1.0
Fig. 2 Kaplan-Meier survival curve for patients undergoing TAVI,
AVR and MT
20 Neth Heart J (2012) 20:16–23approve patients for TAVI, which is subsequently used in the
PARTNER trial [1]. Moreover, randomisation to TAVI or
AVR in the SURgery and Transcatheter Aortic Valve
Implantation (SURTAVI) trial will be based upon clinical
judgement by the Heart Team but not a risk score. The latter
will only be used as criterion for entry into the Heart Team
discussion [6].
The outcome in the TAVI group in the present study is
consistent with the findings of the multi-centre observa-
tional registries [14–18]. The worst complications are death
and stroke. Conceptually safety will increase when less sick
patients receive TAVI. It remains to be elucidated whether
stroke can be reduced by the use of embolic protection
devices during the procedure. As mentioned, the most
frequent complications are bleeding and vascular compli-
cations. Patient-related factors may play a role but are not
theonlyones.Atpresentthereisnofullyprovenpercutaneous
closure technique. Since bleeding and vascular complications
are inherently associated with a series of ensuing events
(e.g. transfusion) and complications (e.g. anaemia, renal
dysfunction) which in turn affect short- and long-term
outcome, surgical access and closure of the arterial entry site
should be considered [19–23]. The need for pacemaker
insertion is predominantly a device-related phenomenon. A
consistently higher frequency of new pacemaker implanta-
tion after MCS implantation (up to 49%) than after Edwards
implantation (up to 27%) is reported [24, 25]. This is not
without clinical importance since abnormal conduction
may impair left ventricular ejection fraction recovery after
TAVI [26].
Follow-upwas characterisedbya highincidence ofcardiac
and non-cardiovascular events. As for immediate outcome, it
is conceivable that long-term outcome will be better in less
sickpatients. Thisisthe subject ofinvestigationinanongoing
Danish study in which age ≥70 is the main selection criterion
for random allocation to TAVI or AVR. (ClinicalTrials.gov,
Identifier: NCT01057173).
In the present study, outcome was poor in patients who
continued MT. MT was continued mainly because of Heart
Team rejection for TAVI because of comorbidity. Yet, a
substantial number of patients refused valve implantation/
replacement. Patient preference intrinsically is bi-directional
and will play an increasing role in treatment decisions due to
increased public awareness. This puts the medical community
Table 3 Adverse events beyond 30 days after TAVI, AVR and medical treatment
TAVI
a AVR
a Medical
a
All (n=106) Fatal (n=40) All (n=10) Fatal (n=5) Fatal (n=59)
Cardiac 46 (43) 19 (48) 5 (50) 1 (20) 31 (53)
Heart failure 13 (12) 4 (10) 4 (40) 1 (20) 19 (32)
Sudden death 8 (8) 8 (20) 0 0 9 (15)
Myocardial infarction 2 (2) 2 (5) 1 (20) 0 1 (2)
Cardiac re-intervention 3 (3)
1 000 0
Stroke or TIA 11 (10)
2 4 (10) 0 0 2 (3)
Pacemaker implantation 9 (9) 1 (3)
3 00 0
Non-cardiac 56 (53) 21 (52) 5 (50) 4 (80) 9 (15)
Infection 17 (16) 8 (20) 1 (10) 1 (20) 5 (8)
Renal failure 7 (7) 4 (10) 2 (20) 2 (40) 0
Vascular 3 (3) 0 0 0 0
Bleeding (non-cranial) 3 (3) 1 (3) 1 (10) 0 0
Neoplasm 9 (8) 4 (10) 0 0 1 (2)
Metabolic disease 2 (2) 2 (5) 0 0 0
Other 15 (14) 2 (5)
4 1 (10) 1 (20)
5 3 (5)
6
Unknown 4 (4) 0 0 0 19 (32)
aMedian follow-up was 298 (IQR: 107–688) days in the TAVI group, 836 (IQR: 327–1269) days in the AVR group and 456 (IQR: 187–869) days
in the medical group
1Re-interventions before discharge included AVR (n=1) and post-implantation balloon aortic valvuloplasty (n=2)
2Including TIA (n=4); of the 11 events, 9 were ischaemic of which 2 fatal and 2 were haemorrhagic, both of which fatal
3Pneumothorax following pacemaker implantation (n=1)
4Blood transfusion reaction (n=1), euthanasia (n=1)
5Delirium (n=1)
6Obstructive pulmonary disease (n=2), lung emboli (n=1)
Neth Heart J (2012) 20:16–23 21under pressure since the position statement paper on
TAVI advocates not to include patient preference in the
treatment decision [4]. It also raises an ethical issue since
one may question whether one has the right to refuse a
treatment modality if a patient who is adequately informed
about treatment options, outcomes and the presence or
absence of future treatment possibilities in case of failure
of the index treatment persists in his/her treatment
preference.
Conclusion
Up to 65 and 7% of the patients with aortic stenosis who
are referred for TAVI undergo TAVI and AVR with
promising results. Patients who are rejected or refuse valve
replacement have a dismal prognosis.
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